Second- and third-line treatment of metastatic breast cancer with gemcitabine

被引：9
|
作者：
Brodowicz, T
Möslinger, R
Herscovici, V
Vaclavik, I
Wiltschke, C
Kubista, E
Zielinski, C
机构：
[1] Univ Vienna, Clin Div Oncol, A-1010 Vienna, Austria
[2] Univ Vienna, Chair Med Expt Oncol, A-1010 Vienna, Austria
[3] Univ Vienna, Dept Obstet & Gynaecol, A-1010 Vienna, Austria
[4] Univ Vienna, Dept Internal Med 1, A-1010 Vienna, Austria
来源：
EUROPEAN JOURNAL OF CANCER | 1998年 / 34卷
关键词：
D O I：
10.1016/S0959-8049(98)80169-X
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
180
引用
收藏
页码：S44 / S44
页数：1
相关论文
共 50 条
  • [41] Proactive Transitioning to Third-Line Treatment in Metastatic Colorectal Cancer
    Bekaii-Saab, Tanios S.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (01) : 5 - 7
  • [42] RESULTS OF BEVACIZUMAB IN COMBINATION WITH FIRST-LINE, SECOND-, AND THIRD-LINE CHEMOTHERAPY IN METASTATIC COLORECTAL CANCER: LONG TERM FOLLOW UP
    Castano, A.
    ANNALS OF ONCOLOGY, 2010, 21 : 35 - 36
  • [43] Optimizing Administration of Third-Line Treatment in Metastatic Colorectal Cancer
    Prager, Gerald W.
    Ducreux, Michel
    Argiles, Guillem
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (12) : 1 - 20
  • [44] Pemetrexed as a Component of First-, Second- and Third-line Chemotherapy in Treating Patients with Metastatic Lung Adenocarcinoma
    Huang, Xin-En
    Tian, Guang-Yu
    Cao, Jie
    Xu, Xia
    Lu, Yan-Yan
    Wu, Xue-Yan
    Liu, Jin
    Shi, Lin
    Xiang, Jin
    ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2013, 14 (11) : 6663 - 6667
  • [45] Chemothery (pacitaxol or irinotecan), plus apatinib and sintilimab as second-/third-line treatment for advanced gastric cancer.
    Deng, Ting
    Zhang, Le
    Duan, Jingjing
    Li, Hongli
    Ge, Shaohua
    Bai, Ming
    Ning, Tao
    Yang, Yuchong
    Ji, Zhi
    Liu, Rui
    Wang, Xia
    Zhang, Haiyang
    Ba, Yi
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [46] Amrubicin as second- or third-line treatment for patients with HER2-negative metastatic breast cancer (MBC): A phase II trial of the Sarah Cannon Research Institute (SCRI)
    Barton, John H.
    Raefsky, Eric
    Harwin, William N.
    Inclan, Alejandro A.
    Miletello, Gerald
    Hainsworth, John D.
    Burris, Howard A.
    Yardley, Denise Aysel
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [47] Clinical evidence for second- and third-line treatment options in advanced non-small cell lung cancer
    de Marinisa, Filippo
    Grossi, Francesco
    ONCOLOGIST, 2008, 13 : 14 - 20
  • [48] Second- or Third-Line Therapy of non-operable, locally advanced or metastatic Renal Cell Carcinoma
    Rexer, Heidrun
    Retz, Margitta
    Steiner, Thomas
    AKTUELLE UROLOGIE, 2021, 52 (05) : 425 - 426
  • [49] Gemcitabine plus UFT combination chemotherapy as second- or third-line therapy in non-small cell lung cancer : a pilot study
    Nishimura, Naoki
    Sugiura, Rika
    Ueda, Hirotaka
    Ono, Hiroshi
    Horinouchi, Hidehito
    Uchiyama, Noboru
    Chohnabayashi, Naohiko
    JOURNAL OF MEDICAL INVESTIGATION, 2008, 55 (3-4): : 260 - 266
  • [50] Gemcitabine and capecitabine as third-line treatment in patients with metastatic colorectal cancer after failure of irinotecan and oxaliplatin.
    Qiu, M.
    Bi, F.
    Liu, J.
    Li, Q.
    Yi, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
12345